查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1914576

中樞神經系統治療市場－全球產業規模、佔有率、趨勢、機會及預測（依藥物類別、適應症、給藥途徑、最終用戶、分銷管道、地區和競爭格局分類），2021-2031年

Central Nervous System Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Application, By Route of Administration, By End User, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球中樞神經系統治療市場預計將從2025年的1,152.1億美元成長至2031年的1,824.2億美元，複合年成長率（CAGR）為7.96%。這些治療藥物旨在治療影響大腦和脊髓的神經和精神疾病，例如阿茲海默症和憂鬱症。推動這一成長的關鍵因素包括全球人口快速老化及其導致的神經退化性疾病的增加，以及全球對精神健康問題的日益關注，這都促進了對更有效藥物治療的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 1152.1億美元
市場規模：2031年 1824.2億美元
複合年成長率：2026-2031年 7.96%
成長最快的細分市場 多發性硬化症
最大的市場 亞太地區

然而，由於開發能夠穿透血腦障壁的藥物涉及極其複雜的科學原理，該行業面臨許多重大挑戰。血腦障壁往往導致臨床試驗的高失敗率，而這種複雜性也會增加研發成本和延長研發週期，從而限制市場成長。為了說明克服這些挑戰所需的巨額投資，歐洲製藥工業協會聯合會（EFPIA）估計，到2024年，以研發為基礎的製藥業將在歐洲的研發領域投入550億歐元。

市場促進因素

全球神經系統和精神疾病盛行率的不斷上升是推動全球中樞神經系統治療市場成長的主要因素。隨著預期壽命的延長，神經退化性疾病的累積風險也在增加，導致需要長期藥物治療的患者群體不斷擴大。精神疾病的廣泛發病進一步加劇了這一趨勢，因為精神疾病需要優先獲得治療。健康指標與評估研究所 (IHME) 於 2024 年 3 月在《刺胳針神經病學》雜誌上發表的一項研究凸顯了這場健康危機的嚴重性。該研究估計，全球有超過 34 億人患有神經系統疾病，使其成為全球疾病和殘疾的主要原因之一。

同時，強大的臨床開發平臺和不斷成長的神經科學研發投入正在推動市場發展。製藥公司正積極尋求策略併購和聯盟，以獲取新的藥物作用機制，尤其是在思覺失調症和阿茲海默症複雜疾病領域，從而加速治療藥物的商業化進程，並克服血腦障壁滲透性等障礙。例如，2023年12月，百時美施貴寶同意以140億美元的股票收購Karuna Therapeutics，以增強其精神科產品以金額為準。此外，阿茲海默症協會預測，到2024年，美國阿茲海默症和其他失智症患者的醫療總費用將達到3,600億美元，凸顯了有效治療方法的巨大商業性潛力。

市場挑戰

全球中樞神經系統治療藥物市場面臨的主要限制因素是開發能夠有效穿過血腦障壁的藥物的科學難度。這種生物屏障會選擇性地阻止許多潛在療法到達大腦靶區，導致極高的失敗率，因為即使臨床前數據積極的化合物，在臨床試驗中也往往無法證明其安全性和有效性。因此，企業不得不接受漫長的研發週期，並承擔神經系統研究舉措相關的高昂財務風險。

應對這些風險所需的大量資源限制了參與企業數量，並壓縮了成功藥物的利潤空間，這不僅為小規模的營業單位設置了障礙，還延緩了新治療方法的上市。生物技術與創新組織（BIO）的數據凸顯了這些挑戰的嚴峻性。該組織報告稱，到2024年，新療法候選藥物的臨床開發成功率約為6.7%。與成功率較高的治療領域相比，這種較低的核准可能性往往會抑制對中樞神經系統（CNS）領域的投資，從而阻礙整體市場擴張。

市場趨勢

市場的一個關鍵轉變是神經退化性疾病治療領域向緩解疾病生物製藥的轉型，這使得治療重點從緩解症狀轉向阿茲海默症潛在病因的標靶治療。這一趨勢主導由抗澱粉樣蛋白單株抗體的商業化所推動，這類抗體能夠清除斑塊沉積並延緩認知衰退，其發展正在改變收入模式，並刺激對診斷和輸注基礎設施的投資。鑑於這些治療方法的快速普及，Eisai在2024年11月的新聞稿中宣布，預計其阿茲海默症治療藥物Rekenvi在截至2025年3月的會計年度全球銷售額將達到425億日圓。

同時，利用人工智慧（AI）識別中樞神經系統（CNS）標靶正在加速發現有前景的候選藥物，並降低神經系統藥物研發的傳統失敗率。製藥公司正擴大與人工智慧專家合作，利用機器學習演算法分析大規模生物資料集，從而實現對藥物-標靶相互作用的精準預測，並在臨床試驗前最佳化分子結構。例如，Formation Bio在2024年6月的新聞稿中宣布，已獲得3.72億美元的D輪融資，賽諾菲也參與了此次資金籌措，旨在增強其人工智慧驅動的藥物發現能力。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球中樞神經系統藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物類別（多發性硬化症藥物、抗精神病藥物、抗癲癇藥物、止痛藥/麻醉劑、抗巴金森氏症藥物、其他）
    • 依應用領域（神經退化性疾病、精神健康與創傷、神經血管疾病、感染疾病、中樞神經系統癌症、其他）
    • 依給藥途徑（口服、腸外、其他）
    • 依最終使用者（醫院、診所、診斷檢查室等）分類
    • 按分銷管道（醫院藥房、網路藥房、零售藥房）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美中樞神經系統治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲中樞神經系統藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區中樞神經系統治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲中樞神經系統藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲中樞神經系統藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球中樞神經系統治療市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Pfizer Inc.
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Novartis International AG
  • Roche Holding AG
  • Bristol-Myers Squibb Company
  • Sanofi SA
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • AstraZeneca plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 7322

The Global Central Nervous System Therapeutics Market is projected to expand from USD 115.21 billion in 2025 to USD 182.42 billion by 2031, reflecting a CAGR of 7.96%. These therapeutics consist of pharmaceutical interventions aimed at treating neurological and psychiatric conditions affecting the brain and spinal cord, such as Alzheimer's disease and depression. Key factors fueling this growth include rapidly aging global demographics and the resulting increase in neurodegenerative diseases, alongside a rising worldwide awareness of mental health issues that sustains demand for effective pharmacological treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 115.21 Billion
Market Size 2031USD 182.42 Billion
CAGR 2026-20317.96%
Fastest Growing SegmentMultiple Sclerosis
Largest MarketAsia Pacific

Conversely, the industry faces significant obstacles due to the scientific intricacies involved in developing drugs capable of crossing the blood-brain barrier, a hurdle that frequently contributes to high failure rates in clinical trials. This complexity leads to increased development costs and extended timelines, which can constrain market growth. Highlighting the massive financial resources dedicated to navigating these challenges, the European Federation of Pharmaceutical Industries and Associations estimated that the research-based pharmaceutical industry invested €55 billion in research and development across Europe in 2024.

Market Driver

The rising global prevalence of neurological and psychiatric disorders serves as the primary engine for growth in the Global Central Nervous System Therapeutics Market. As life expectancy rises, the cumulative risk of neurodegenerative conditions increases, creating a larger patient population requiring long-term pharmaceutical management, a trend further amplified by the widespread occurrence of mental health disorders that necessitate prioritized therapeutic access. The magnitude of this health crisis was highlighted by a study published in 'The Lancet Neurology' by the Institute for Health Metrics and Evaluation in March 2024, which estimated that over 3.4 billion people worldwide are affected by neurological conditions, making them the leading cause of global ill health and disability.

Concurrently, the market is boosted by a strong clinical pipeline and increased capital investment in neuroscience research and development. Pharmaceutical companies are actively pursuing strategic mergers and partnerships to acquire novel mechanisms of action, particularly for complex conditions like schizophrenia and Alzheimer's disease, thereby accelerating the commercialization of treatments and addressing barriers such as blood-brain barrier penetration. For instance, Bristol Myers Squibb agreed to acquire Karuna Therapeutics for an equity value of $14 billion in December 2023 to enhance its psychiatry portfolio, while the Alzheimer's Association projected in 2024 that total care payments for Americans with Alzheimer's and other dementias would reach $360 billion, underscoring the immense commercial potential for effective therapies.

Market Challenge

A major constraint on the global central nervous system therapeutics market is the scientific difficulty of creating drugs that can successfully traverse the blood-brain barrier. This biological filter selectively blocks many potential treatments from reaching targeted areas in the brain, resulting in exceptionally high attrition rates during clinical trials where compounds frequently fail to prove safety or efficacy in humans despite favorable preclinical data. Consequently, companies are compelled to lengthen development timelines and accept higher financial risks associated with neurological research initiatives.

The significant resources needed to manage these risks restrict the number of market participants and compress profit margins for successful drugs, creating hurdles for smaller entities and slowing the launch of new therapies. The severity of these challenges is evident in data from the Biotechnology Innovation Organization, which reported in 2024 that the clinical development success rate for new therapeutic candidates was approximately 6.7 percent. This low likelihood of approval tends to deter investment in CNS compared to therapeutic areas with higher success rates, thereby inhibiting the overall expansion of the market.

Market Trends

A pivotal transformation in the market is the shift toward disease-modifying biologics for neurodegenerative disorders, moving the focus from symptomatic relief to targeting underlying pathologies like Alzheimer's disease. This trend is led by the commercialization of anti-amyloid monoclonal antibodies capable of clearing plaque deposits and slowing cognitive decline, a development that is altering revenue models and spurring investment in diagnostic and infusion infrastructure. Reflecting the rapid uptake of these therapies, Eisai Co., Ltd. projected in a November 2024 press release that global revenue for its Alzheimer's treatment, Leqembi, would reach JPY 42.5 billion for the fiscal year ending March 2025.

Simultaneously, the adoption of artificial intelligence for CNS target identification is expediting the discovery of viable drug candidates and addressing historic failure rates in neurological development. Pharmaceutical firms are increasingly collaborating with AI-specialized companies to utilize machine learning algorithms that analyze massive biological datasets, enabling precise prediction of drug-target interactions and optimization of molecular structures prior to clinical testing. Demonstrating the significant capital flowing into this area, Formation Bio announced in a June 2024 press release that it secured $372 million in Series D financing, with participation from Sanofi, to enhance its AI-driven drug development capabilities.

Key Market Players

  • Pfizer Inc.
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Novartis International AG
  • Roche Holding AG
  • Bristol-Myers Squibb Company
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • AstraZeneca plc

Report Scope

In this report, the Global Central Nervous System Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Central Nervous System Therapeutics Market, By Drug Class

  • Multiple Sclerosis
  • Antipsychotic
  • Antiepileptics
  • Analgesics & Anesthetics
  • Anti-Parkinson
  • Others

Central Nervous System Therapeutics Market, By Application

  • Neurodegenerative Diseases
  • Mental Health and Trauma
  • Neurovascular Diseases
  • Infectious Diseases
  • CNS Cancer
  • Others

Central Nervous System Therapeutics Market, By Route of Administration

  • Oral
  • Parenteral
  • Others

Central Nervous System Therapeutics Market, By End User

  • Hospital
  • Clinics
  • Diagnostic Laboratories
  • Others

Central Nervous System Therapeutics Market, By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Central Nervous System Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Central Nervous System Therapeutics Market.

Available Customizations:

Global Central Nervous System Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Central Nervous System Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Multiple Sclerosis, Antipsychotic, Antiepileptics, Analgesics & Anesthetics, Anti-Parkinson, Others)
    • 5.2.2. By Application (Neurodegenerative Diseases, Mental Health and Trauma, Neurovascular Diseases, Infectious Diseases, CNS Cancer, Others)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
    • 5.2.4. By End User (Hospital, Clinics, Diagnostic Laboratories, Others)
    • 5.2.5. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Central Nervous System Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Application
    • 6.2.3. By Route of Administration
    • 6.2.4. By End User
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Central Nervous System Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By End User
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Canada Central Nervous System Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By End User
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Mexico Central Nervous System Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By End User
        • 6.3.3.2.5. By Distribution Channel

7. Europe Central Nervous System Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Application
    • 7.2.3. By Route of Administration
    • 7.2.4. By End User
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Central Nervous System Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By End User
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. France Central Nervous System Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By End User
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Central Nervous System Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By End User
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Central Nervous System Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By End User
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Central Nervous System Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By End User
        • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Central Nervous System Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Application
    • 8.2.3. By Route of Administration
    • 8.2.4. By End User
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Central Nervous System Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By End User
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Central Nervous System Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By End User
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. Japan Central Nervous System Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By End User
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. South Korea Central Nervous System Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By End User
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Central Nervous System Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By End User
        • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Central Nervous System Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Application
    • 9.2.3. By Route of Administration
    • 9.2.4. By End User
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Central Nervous System Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By End User
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. UAE Central Nervous System Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By End User
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. South Africa Central Nervous System Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By End User
        • 9.3.3.2.5. By Distribution Channel

10. South America Central Nervous System Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Application
    • 10.2.3. By Route of Administration
    • 10.2.4. By End User
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Central Nervous System Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By End User
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Colombia Central Nervous System Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By End User
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. Argentina Central Nervous System Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By End User
        • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Central Nervous System Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Eli Lilly and Company
  • 15.3. Johnson & Johnson Services, Inc.
  • 15.4. Novartis International AG
  • 15.5. Roche Holding AG
  • 15.6. Bristol-Myers Squibb Company
  • 15.7. Sanofi S.A.
  • 15.8. GlaxoSmithKline plc
  • 15.9. AbbVie Inc.
  • 15.10. AstraZeneca plc

16. Strategic Recommendations

17. About Us & Disclaimer